$HRMY
Harmony Biosciences Holdings Inc

2021 Form 10-K Financial Statement

#000155837022002257 Filed on February 28, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $305.4M $56.29M $159.7M
YoY Change 91.21% 2564.59%
Cost Of Revenue $55.52M $9.920M $27.74M
YoY Change 100.15% 1658.91%
Gross Profit $249.9M $46.37M $132.0M
YoY Change 89.33% 2887.87%
Gross Profit Margin 81.82% 82.38% 82.64%
Selling, General & Admin $132.0M $30.99M $95.57M
YoY Change 38.15% 18.39%
% of Gross Profit 52.83% 66.83% 72.4%
Research & Development $30.37M $7.620M $19.45M
YoY Change 56.14% -72.06%
% of Gross Profit 12.15% 16.43% 14.73%
Depreciation & Amortization $416.0K $4.380M $394.0K
YoY Change 5.58% 45.51% -0.25%
% of Gross Profit 0.17% 9.45% 0.3%
Operating Expenses $162.4M $38.61M $115.0M
YoY Change 41.19% -23.49%
Operating Profit $87.53M $7.760M $16.99M
YoY Change 415.29% -111.64%
Interest Expense -$23.97M -$7.970M -$28.22M
YoY Change -15.06% 364.68%
% of Operating Profit -27.39% -102.71% -166.14%
Other Income/Expense, Net $16.00K $0.00 -$3.071M
YoY Change -100.52%
Pretax Income $37.43M -$210.0K -$36.94M
YoY Change -201.31% -75.69%
Income Tax $2.831M $0.00 $0.00
% Of Pretax Income 7.56%
Net Earnings $34.60M -$210.0K -$36.94M
YoY Change -193.65% -75.69%
Net Earnings / Revenue 11.33% -0.37% -23.13%
Basic Earnings Per Share $0.60 -$2.48
Diluted Earnings Per Share $0.58 -$3.691K -$2.48
COMMON SHARES
Basic Shares Outstanding 57.53M 56.89M 25.77M
Diluted Shares Outstanding 59.21M 25.77M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $234.3M $228.6M $228.6M
YoY Change 2.5% 833.06%
Cash & Equivalents $234.3M $228.6M $228.6M
Short-Term Investments
Other Short-Term Assets $10.86M $1.302M $8.300M
YoY Change 30.78% 398.85% 388.24%
Inventory $4.432M $3.823M $3.800M
Prepaid Expenses $6.959M
Receivables $34.84M $22.18M $22.20M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $284.4M $262.9M $262.9M
YoY Change 8.19% 734.65% 734.6%
LONG-TERM ASSETS
Property, Plant & Equipment $820.0K $938.0K $900.0K
YoY Change -8.89% -29.47% -30.77%
Goodwill
YoY Change
Intangibles $162.3M
YoY Change 124.9%
Long-Term Investments
YoY Change
Other Assets $4.265M $152.0K $900.0K
YoY Change 373.89% -83.85% -47.06%
Total Long-Term Assets $149.0M $164.2M $164.2M
YoY Change -9.25% 118.31% 118.35%
TOTAL ASSETS
Total Short-Term Assets $284.4M $262.9M $262.9M
Total Long-Term Assets $149.0M $164.2M $164.2M
Total Assets $433.4M $427.1M $427.1M
YoY Change 1.49% 300.25% 300.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.001M $2.556M $2.600M
YoY Change -61.5% -59.81% -59.38%
Accrued Expenses $49.41M $122.7M $131.7M
YoY Change -62.48% 2131.4% 882.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M
YoY Change
Total Short-Term Liabilities $53.78M $134.5M $134.5M
YoY Change -60.02% 576.35% 575.88%
LONG-TERM LIABILITIES
Long-Term Debt $190.0M $194.3M $194.3M
YoY Change -2.22% 98.32% 98.47%
Other Long-Term Liabilities $3.177M $1.105M $1.100M
YoY Change 188.82% 577.91% 120.0%
Total Long-Term Liabilities $193.2M $195.4M $195.4M
YoY Change -1.15% 98.54% 98.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.78M $134.5M $134.5M
Total Long-Term Liabilities $193.2M $195.4M $195.4M
Total Liabilities $246.9M $329.9M $329.9M
YoY Change -25.15% 178.89% 178.87%
SHAREHOLDERS EQUITY
Retained Earnings -$488.2M
YoY Change 15.45%
Common Stock $585.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $186.5M $97.18M $97.20M
YoY Change
Total Liabilities & Shareholders Equity $433.4M $427.1M $427.1M
YoY Change 1.49% 300.25% 300.28%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income $34.60M -$210.0K -$36.94M
YoY Change -193.65% -75.69%
Depreciation, Depletion And Amortization $416.0K $4.380M $394.0K
YoY Change 5.58% 45.51% -0.25%
Cash From Operating Activities $98.56M $10.04M -$2.985M
YoY Change -3401.74% -121.16% -96.04%
INVESTING ACTIVITIES
Capital Expenditures $298.0K $0.00 $2.000K
YoY Change 14800.0% -100.0% -98.66%
Acquisitions
YoY Change
Other Investing Activities -$2.000M -$2.000M
YoY Change 0.0% -96.15%
Cash From Investing Activities -$100.3M -$2.000M -$2.002M
YoY Change 4909.89% -97.4% -98.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $30.00M -$135.3M
YoY Change -122.18%
Debt Paid & Issued, Net $500.0K
YoY Change
Cash From Financing Activities 7.419M -1.160M 209.2M
YoY Change -96.45% -101.59% 45.48%
NET CHANGE
Cash From Operating Activities 98.56M 10.04M -2.985M
Cash From Investing Activities -100.3M -2.000M -2.002M
Cash From Financing Activities 7.419M -1.160M 209.2M
Net Change In Cash 5.678M 6.880M 204.2M
YoY Change -97.22% -113.38% -447.14%
FREE CASH FLOW
Cash From Operating Activities $98.56M $10.04M -$2.985M
Capital Expenditures $298.0K $0.00 $2.000K
Free Cash Flow $98.26M $10.04M -$2.987M
YoY Change -3389.55% -63.66% -96.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001802665
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56890569
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58825769
CY2019 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2019 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1217
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q2 hrmy Operating Lease Office Space
OperatingLeaseOfficeSpace
15000
CY2018Q4 hrmy Operating Lease Office Space
OperatingLeaseOfficeSpace
13000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1217
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Plymouth Meeting
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19462
CY2021 dei City Area Code
CityAreaCode
484
CY2021 dei Local Phone Number
LocalPhoneNumber
539-9800
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 value per share
CY2021 dei Trading Symbol
TradingSymbol
HRMY
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 hrmy Period Of Change In Ownership
PeriodOfChangeInOwnership
P3Y
CY2020Q4 us-gaap Warrants And Rights Outstanding Change In Valuation Technique
WarrantsAndRightsOutstandingChangeInValuationTechnique
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39450
CY2021 dei Entity Registrant Name
EntityRegistrantName
HARMONY BIOSCIENCES HOLDINGS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2279923
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
630 W.
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Germantown Pike
CY2021 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 215
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
false
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
730500000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58872147
CY2021 dei Auditor Firm
AuditorFirmId
34
CY2021 dei Auditor Name
AuditorName
Deloitte & Touche LLP
CY2021 dei Auditor Location
AuditorLocation
Chicago, Illinois
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
234309000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228631000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34843000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22176000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4432000
CY2020Q4 us-gaap Inventory Net
InventoryNet
3823000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7637000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6959000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3218000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1302000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
284439000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
262891000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
820000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
938000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
143919000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
162343000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3515000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
152000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
149004000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
164183000
CY2021Q4 us-gaap Assets
Assets
433443000
CY2020Q4 us-gaap Assets
Assets
427074000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1001000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2556000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9165000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8942000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40249000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
122727000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1360000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
314000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53775000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
134539000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189984000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
194250000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3177000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1105000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
193161000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
195355000
CY2021Q4 us-gaap Liabilities
Liabilities
246936000
CY2020Q4 us-gaap Liabilities
Liabilities
329894000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58825769
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56890569
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
640104000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
585374000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453598000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-488195000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186507000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
97180000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
433443000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
427074000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
305440000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
159742000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5995000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
55518000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
27738000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1577000
CY2021 us-gaap Gross Profit
GrossProfit
249922000
CY2020 us-gaap Gross Profit
GrossProfit
132004000
CY2019 us-gaap Gross Profit
GrossProfit
4418000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30367000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19448000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69595000
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
68118000
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
55824000
CY2019 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
44318000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
63909000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39746000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36409000
CY2021 us-gaap Operating Expenses
OperatingExpenses
162394000
CY2020 us-gaap Operating Expenses
OperatingExpenses
115018000
CY2019 us-gaap Operating Expenses
OperatingExpenses
150322000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
87528000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
16986000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-145904000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26146000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-22639000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3071000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-23970000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-28220000
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6073000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
37428000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36944000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-151977000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2831000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
34597000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36944000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-151977000
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
26904000
CY2019 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
35231000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
34597000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-63848000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-187208000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.60
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.48
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-24.07
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.58
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.48
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-24.07
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57531540
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25772419
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7777441
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59205213
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25772419
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7777441
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
293000000
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
324201000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-242673000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-151977000
CY2019 hrmy Temporary Equity Stock Issued During Period Shares New Issues
TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
25510205
CY2019 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
48868000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
85000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9909000
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
318510205
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
411275000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-422862000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36944000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
135435000
CY2020 hrmy Temporary Equity Share Converted To Permanent Equity
TemporaryEquityShareConvertedToPermanentEquity
-318510205
CY2020 hrmy Temporary Equity Value Converted To Permanent Equity
TemporaryEquityValueConvertedToPermanentEquity
-444715000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
444716000
CY2020 hrmy Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
5468000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
299000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4693000
CY2020 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
167000
CY2020 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
17000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
97180000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
34597000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29700000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9371000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15659000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186507000
CY2021 us-gaap Profit Loss
ProfitLoss
34597000
CY2020 us-gaap Profit Loss
ProfitLoss
-36944000
CY2019 us-gaap Profit Loss
ProfitLoss
-151977000
CY2021 us-gaap Depreciation
Depreciation
416000
CY2020 us-gaap Depreciation
Depreciation
394000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
609000
CY2019 us-gaap Depreciation
Depreciation
395000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18424000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9843000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2815000
CY2020 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
2000000
CY2019 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
52000000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
15659000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4693000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
9909000
CY2021 hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
446000
CY2020 hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
497000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3109000
CY2019 us-gaap Paid In Kind Interest
PaidInKindInterest
2538000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2238000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2412000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
592000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26146000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-22639000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12667000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
17922000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4255000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2735000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1088000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1591000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6563000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1467000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
64000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-789000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
420000
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1555000
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-3804000
CY2019 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
4898000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
17263000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
18450000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7763000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-146000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
157000
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-73000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
98557000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2985000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75436000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
298000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
149000
CY2021 hrmy Cash Paid For Milestones
CashPaidForMilestones
100000000
CY2020 hrmy Cash Paid For Milestones
CashPaidForMilestones
2000000
CY2019 hrmy Cash Paid For Milestones
CashPaidForMilestones
127000000
CY2019 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
50000000
CY2019 hrmy Payment Of Preferred Stock Issuance Costs
PaymentOfPreferredStockIssuanceCosts
1132000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-100298000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2002000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-127149000
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
200000000
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
100000000
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
9152000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
147628000
CY2020 hrmy Payment Of Initial Public Offering Issuance Costs
PaymentOfInitialPublicOfferingIssuanceCosts
12193000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30000000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
200000000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5804000
CY2019 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5184000
CY2021 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
200000000
CY2020 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
102538000
CY2021 hrmy Payments Of Extinguishment Of Debt Exit Fees
PaymentsOfExtinguishmentOfDebtExitFees
22000000
CY2020 hrmy Payments Of Extinguishment Of Debt Exit Fees
PaymentsOfExtinguishmentOfDebtExitFees
18047000
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
500000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9371000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
299000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
85000
CY2020 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
167000
CY2020 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
17000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7419000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
209161000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
143769000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5678000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
204174000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-58816000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229381000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25207000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84023000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235059000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229381000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25207000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
19830000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
26203000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
4230000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2875000
CY2020 hrmy Warrant Financing
WarrantFinancing
2359000
CY2020 hrmy Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
5468000
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
410239
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-8.215
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453598000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-488195000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
234309000
CY2021 hrmy Number Of Approved Commercial Products
NumberOfApprovedCommercialProducts
1
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 40pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the Consolidated Financial Statements, including the notes thereto, and elsewhere in this report. Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19.</p>
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
234309000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228631000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235059000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229381000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 38pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits in this institution may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also subject to credit risk from its trade receivables related to its product sales. The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of December 31, 2021, three customers accounted for 100% of gross accounts receivable, Accredo Health Group, Inc. (“Accredo”), which accounted for 40% of gross accounts receivable; PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 31% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 29% of gross accounts receivable. As of December 31, 2020, three customers accounted for 100% of gross accounts receivable; CVS Caremark, which accounted for 44% of gross accounts receivable, Pantherx, which accounted for 23% of gross accounts receivable and Accredo, which accounted for 33% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For the year ended December 31, 2021, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 36% of gross product revenues; Pantherx accounted for 35% of gross product revenues; and Accredo accounted for 29% of gross product revenues. For the year ended December 31, 2020, three customers accounted for 100% of gross product revenues, CVS Caremark accounted for 40% of gross product revenues; Pantherx accounted for </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">33% of gross products revenues; and Accredo accounted for 27% of gross product revenues. For the year ended December 31, 2019, two customers accounted for 88% of gross product revenues; CVS Caremark accounted for 59% of gross product revenues and Pantherx accounted for 29% of gross product revenues.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single source supplier for its product, product candidates and their active pharmaceutical ingredient.</p>
CY2019 hrmy Inventory Sold Expensed As Research And Development Expense
InventorySoldExpensedAsResearchAndDevelopmentExpense
1323000
CY2021 us-gaap Advertising Expense
AdvertisingExpense
19558000
CY2020 us-gaap Advertising Expense
AdvertisingExpense
13301000
CY2019 us-gaap Advertising Expense
AdvertisingExpense
7072000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
On November 15, 2019 the Company modified the award to remove the performance condition
CY2019 us-gaap Other Noncash Expense
OtherNoncashExpense
8400
CY2020Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2021Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2021Q1 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
986000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
396000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1787000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2660000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2108000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
941000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
4881000
CY2020Q4 us-gaap Inventory Gross
InventoryGross
3997000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
449000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
174000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4432000
CY2020Q4 us-gaap Inventory Net
InventoryNet
3823000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18424000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9843000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2815000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
18570000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
18570000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
18570000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
18570000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
18570000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
51069000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
143919000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
175000000
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
175000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
31081000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12657000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
143919000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
162343000
CY2019Q3 hrmy License Agreement Additional Milestone Payments Due
LicenseAgreementAdditionalMilestonePaymentsDue
102000000
CY2019Q3 hrmy Licensing Agreement Milestone Fees
LicensingAgreementMilestoneFees
2000000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
16396000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9006000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
16396000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9006000
CY2021Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
17141000
CY2020Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
7803000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2125000
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1983000
CY2020Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1905000
CY2021Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
658000
CY2020Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2186000
CY2021Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1645000
CY2020Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1081000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
301000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
746000
CY2020Q4 hrmy Accrued Milestone Payment Current
AccruedMilestonePaymentCurrent
100000000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40249000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
122727000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2000000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
20000000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
155500000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
199500000
CY2021 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
21955000
CY2020 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
26203000
CY2019 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4231000
CY2019 us-gaap Paid In Kind Interest
PaidInKindInterest
2538000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2238000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2412000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
592000
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
24193000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
28615000
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
7361000
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1197000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
686000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
1051000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.038
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3298000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1527000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2233000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3760000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1126000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4480000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.66
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M17D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1551502
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
35.69
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
668782
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
14.19
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
376955
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
24.23
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5716597
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.53
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M2D
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1638000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1521000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
788000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3947000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
187000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3760000
CY2019 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-8.215
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share
CY2019Q4 hrmy Common Stock Number Of Shares Subject To Forfeiture Provisions
CommonStockNumberOfSharesSubjectToForfeitureProvisions
1217285
CY2019Q4 us-gaap Share Based Compensation
ShareBasedCompensation
8400000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5210832
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9909000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
56531000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M24D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.6000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5500
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9580
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9530
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9930
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0066
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0144
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0032
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0056
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0160
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0259
CY2021 hrmy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount
0.0000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16105000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5190000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9909000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16105000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5190000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
34597000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36944000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-151977000
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
26904000
CY2019 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
35231000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
34597000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-63848000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-187208000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.60
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.48
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-24.07
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.58
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.48
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-24.07
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57531540
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25772419
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7777441
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59205213
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25772419
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7777441
CY2021 hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1673673
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4289066
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5670365
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39163208
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3109000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.277
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.076
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
6487000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-6416000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-32508000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2852000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
4198000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-9641000
CY2021 hrmy Valuation Allowance Income Tax Expense Benefit
ValuationAllowanceIncomeTaxExpenseBenefit
-6508000
CY2020 hrmy Valuation Allowance Income Tax Expense Benefit
ValuationAllowanceIncomeTaxExpenseBenefit
2218000
CY2019 hrmy Valuation Allowance Income Tax Expense Benefit
ValuationAllowanceIncomeTaxExpenseBenefit
42149000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2831000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2831000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
6508000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2218000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-42149000
CY2021 hrmy Valuation Allowance Income Tax Expense Benefit
ValuationAllowanceIncomeTaxExpenseBenefit
-6508000
CY2020 hrmy Valuation Allowance Income Tax Expense Benefit
ValuationAllowanceIncomeTaxExpenseBenefit
2218000
CY2019 hrmy Valuation Allowance Income Tax Expense Benefit
ValuationAllowanceIncomeTaxExpenseBenefit
42149000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2831000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.023
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.064
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.114
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.063
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.036
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.173
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.060
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
42460000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
70000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1096000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
71000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1242000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
97462000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1096000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
104116000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1242000
CY2021Q4 hrmy Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
96366000
CY2020Q4 hrmy Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
102874000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
96366000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
45346000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
29739000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
44983000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
6285000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
4075000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
168000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1604000
CY2021Q4 hrmy Deferred Tax Assets Disallowed Interest
DeferredTaxAssetsDisallowedInterest
7635000
CY2020Q4 hrmy Deferred Tax Assets Disallowed Interest
DeferredTaxAssetsDisallowedInterest
7751000
CY2021Q4 hrmy Deferred Tax Assets Lease Obligations Net
DeferredTaxAssetsLeaseObligationsNet
123000
CY2020Q4 hrmy Deferred Tax Assets Lease Obligations Net
DeferredTaxAssetsLeaseObligationsNet
121000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
124000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
65000
CY2021Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
6294000
CY2020Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
100000
CY2021Q4 hrmy Deferred Tax Assets Accrued Rebates
DeferredTaxAssetsAccruedRebates
4564000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
102874000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
96366000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-6508000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
102874000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
100656000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
58507000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-6508000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2218000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
42149000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
96366000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
102874000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
100656000
CY2021 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
These ownership changes may limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups.
CY2021 hrmy Percentage Of Change In Ownership
PercentageOfChangeInOwnership
0.50
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235059000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229381000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3109000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2479000
CY2021Q3 hrmy Related Party Transaction Payment For Advisory Fee
RelatedPartyTransactionPaymentForAdvisoryFee
2300000

Files In Submission

Name View Source Status
0001558370-22-002257-index-headers.html Edgar Link pending
0001558370-22-002257-index.html Edgar Link pending
0001558370-22-002257.txt Edgar Link pending
0001558370-22-002257-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hrmy-20211231.xsd Edgar Link pending
hrmy-20211231x10k.htm Edgar Link pending
hrmy-20211231x10k005.jpg Edgar Link pending
hrmy-20211231x10k006.jpg Edgar Link pending
hrmy-20211231x10k007.jpg Edgar Link pending
hrmy-20211231x10k_htm.xml Edgar Link completed
hrmy-20211231xex21d1.htm Edgar Link pending
hrmy-20211231xex23d1.htm Edgar Link pending
hrmy-20211231xex31d1.htm Edgar Link pending
hrmy-20211231xex31d2.htm Edgar Link pending
hrmy-20211231xex32d1.htm Edgar Link pending
hrmy-20211231xex32d2.htm Edgar Link pending
hrmy-20211231_cal.xml Edgar Link unprocessable
hrmy-20211231_def.xml Edgar Link unprocessable
hrmy-20211231_lab.xml Edgar Link unprocessable
hrmy-20211231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending